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The continuously growing natural killer (NK) cell line NK-
92 is highly cytotoxic against malignant cells of various
origin without affecting normal human cells. Based on
this selectivity, the potential of NK-92 cells for adoptive
therapy is currently being investigated in phase I clinical
studies. To further enhance the antitumoral activity of NK-
92 cells and expand the range of tumor entities suitable
for NK-92-based therapies, here by transduction with ret-
roviral vectors we have generated genetically modified
NK-92 cells expressing chimeric antigen receptors specific
either for the tumor-associated ErbB2 (HER2/neu) anti-
gen or the human Epithelial Cell Adhesion Molecule (Ep-
CAM). Both antigens are overexpressed by many tumors
of epithelial origin. The chimeric antigen receptors consist
of either the ErbB2 specific scFv(FRP5) antibody fragment
or the Ep-CAM specific scFv(MOC31), a flexible hinge
region derived from CD8, and transmembrane and intra-
cellular regions of the CD3 zeta chain.
Transduced NK-92-scFv(FRP5)-zeta or NK-92-
scFv(MOC31)-zeta cells express high levels of the fusion
proteins on the cell surface as determined by FACS analy-
sis. In europium release assays no difference in cytotoxic
activity of NK-92 and transduced NK-92 cells towards
ErbB2 or Ep-CAM negative targets was found. However,
even at low effector to target ratios transduced NK-92 cells
specifically and efficiently lysed established ErbB2 or Ep-
CAM expressing tumor cells that were completely resistant
to cytolytic activity of parental NK-92 cells. Similarly,
ErbB2-positive primary breast cancer cells isolated from
pleural effusions of patients with recurrent disease were
selectively killed by NK-92-scFv(FRP5)-zeta. In an in vivo
model in immunodeficient mice treatment with retar-
geted NK-92-scFv(FRP5)-zeta, but not parental NK-92
cells resulted in markedly delayed growth of ErbB2 trans-
formed cancer cells.
These results demonstrate that efficient retargeting of NK-
92 cytotoxicity can be achieved, and might allow the gen-
eration of potent cell-based therapeutics for the treatment
of ErbB2 and Ep-CAM expressing malignancies. This ther-
apeutic approach might be applicable for a large variety of
different cancers where suitable cell surface antigens have
been identified.
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